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Abstract 
The immune system and the kidneys are closely linked. In health the kidneys contribute 
to immune homeostasis, while components of the immune system mediate many acute 
forms of renal disease and play a central role in progression of chronic kidney disease. 
A dysregulated immune system can have either direct or indirect renal effects. Direct 
immune-mediated kidney diseases are usually a consequence of autoantibodies 
directed against a constituent renal antigen, such as collagen IV in anti-glomerular 
basement membrane disease. Indirect immune-mediated renal disease often follows 
systemic autoimmunity with immune complex formation, but can also be due to 
uncontrolled activation of the complement pathways. Though the range of mechanisms 
of immune dysregulation leading to renal disease is broad, the pathways leading to 
injury are similar. Loss of immune homeostasis in renal disease results in perpetual 
immune cell recruitment and worsening damage to the kidney. Uncoordinated attempts 
at tissue repair, after immune-mediated disease or non-immune mediated injury, result 
in fibrosis of structures important for renal function, eventually leading to kidney failure. 
As renal disease often only manifests clinically when substantial damage has already 
occurred, new diagnostic methods and indeed treatments must be identified to inhibit 
further progression and promote appropriate tissue repair. Studying cases in which 
immune homeostasis is re-established may reveal new treatment possibilities. 
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Introduction 
The kidneys, as a major filter organ for the blood and the key organ responsible for 
maintaining total body water balance and circulatory pressure, receive a rich blood 
supply by which they monitor and modify the functional status of multiple organ 
systems. Besides clearing metabolic waste products, toxins and drugs from our body, 
the kidneys also clear circulating cytokines and bacterial toxins like lipopolysaccharide 
(LPS) and continuously sample blood-borne proteins, contributing to homeostasis of 
the immune system. The removal of cytokines from the blood can limit inflammation [1, 
2], and the clearance of bacterial components reduces would-be immune cell activation 
by pattern recognition receptors (PRRs) [2, 3]. In addition, kidney resident dendritic 
cells (DCs) appear to be very important in maintaining peripheral tolerance [1]. As 85% 
of the water filtered at the glomerulus is immediately reabsorbed by the proximal tubule, 
cells in the distal nephron downstream experience filtered low-molecular weight 
antigens at concentrations up to ten times higher than in the blood itself. These 
antigens are taken up readily by a dense network of DCs, for example via dendrites 
protruding directly into the tubular lumen, enabling these filtered antigens to be 
presented to T cells in renal draining lymph nodes more efficiently than possible 
elsewhere in the body. Through this regular presentation of innocuous antigens in the 
absence of danger signals, potentially autoreactive T cells recognising these low 
molecular weight antigens are inactivated. Thus, the kidneys, in addition to the spleen, 
assist in maintaining peripheral tolerance to circulating antigens such as hormones and 
food proteins [1, 4].  The kidney’s important contribution to immune homeostasis 
becomes especially clear in end stage renal disease (ESRD), where immune function 
is severely compromised. The retention of uraemic toxins and cytokines activates 
innate immune cells leading to a vicious cycle of further cytokine and reactive oxygen 
species production, both contributing to tissue damage and increasing cardiovascular 
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risk. Additionally, lymphocyte number and function decrease, leaving the patient 
functionally immunocompromised and at risk of infection as well as viral-associated 
cancers [2, 5]. 
 
Conversely, the kidneys themselves are also very susceptible to immune mediated 
diseases. Loss of immune homeostasis can adversely affect the kidney either directly 
or indirectly, leading to loss of kidney function. Homeostasis describes the 
physiological condition of a system under normal conditions. In the immune system, 
homeostasis therefore refers to its function and maintenance in the uninfected host [6]. 
However, it could be argued that the inflammatory immune response to infections and 
tissue damage is a normal extension of the immune system’s homeostatic function, as 
long as the immune response resolves. Assuming the latter definition of immune 
homeostasis, loss of homeostasis includes over or under activity of the immune 
response, but not the initial reaction to infection or tissue injury. The following is a brief 
overview of immune-mediated kidney disease, which in accordance with the above 
definition will not include congenital kidney diseases, or those caused by infections or 
sterile injury.  
 
Direct immune-mediated renal disease 
Renal diseases associated with loss of immune homeostasis can be grouped 
according to direct or indirect immune-mediated kidney injury. Direct immune-mediated 
renal disease involves the immune system targeting specific antigens within the kidney; 
while in indirect immune-mediated renal disease, the kidneys are a bystander victim of 
processes resulting from systemic dysregulation of the immune system. Self-antigens 
constituently found in the kidneys are the targets for several autoimmune diseases, 
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which can inflict either renal limited pathology or additionally involve multiple organ 
systems. 
 
Overall, disruption of immune homeostasis leads to direct renal disease through auto-
reactivity of both T and B cells, which can damage the kidneys at different sites. The 
resulting injury shows a range of histologic patterns, which correspond to various 
underlying mechanisms associated with specific treatment responses and renal 
prognosis, but the range of clinical presentations is more limited, highlighting the value 
of renal biopsy in patient management. Continuous insults to epithelial and interstitial 
cells in the kidney result in scarring and diminished renal function, thus leading to the 
establishment of CKD. 
 
Direct targets of the immune system located in the glomerulus 
Classic examples of direct immune-mediated renal disease where the target antigen is 
located in the glomerulus are anti-glomerular basement membrane disease (anti-GBM 
disease), and membranous glomerulonephritis (MGN), which both present clinically 
with glomerular abnormalities, such proteinuria and haematuria, and often progress to 
chronic kidney disease (CKD) and ultimately ESRD. Anti-GBM disease is a form of 
crescentic glomerulonephritis (GN), most often presenting with acute renal 
abnormalities, and in some patients also severe alveolar haemorrhage in the lungs 
(Goodpasture’s syndrome). Circulating autoantibodies bind the NC1 domain of the 
collagen IV α3 chain (α3(IV)NC1) [7]. Interestingly, the epitopes recognized by this 
autoantibody are typically hidden within in the quaternary structure of type IV collagen, 
so that an initial conformational change must occur before the autoantibodies can bind. 
Potential triggers for the unmasking of the autoantigen are still unknown, but once 
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binding has occurred it leads to further conformational changes and thus perpetuation 
of antigen-antibody complex formation [8]. The resulting linear immune deposits along 
glomerular basement membranes, typically composed of IgG antibody and 
complement components, damage the surrounding endothelial cells and podocytes, 
leading to robust immune cell infiltration, inflammation and ultimately fibrosis (Figure 1). 
 
In contrast, MGN is defined by diffuse thickening of the glomerular capillary wall by 
subepithelial immune deposits. Although MGN can be caused by immune complex 
deposition secondary to systemic diseases such as systemic lupus erythematosus 
(SLE), infections such as hepatitis B virus, or in association with malignancy, most 
cases of MGN are primary, and a substantial fraction of these cases are caused by 
autoantibodies against proteins normally expressed by podocytes in the glomerulus. 
The binding of these autoantibodies to their respective podocyte membrane antigens 
activates the classical complement pathway leading to podocyte injury. Podocytes 
react by altering their cytoskeleton and secreting mediators of fibrosis and pro-
inflammatory cytokines. This local glomerular process results in remodelling of the 
glomerular basement membrane and can develop into focal glomerular segmental 
sclerosis; the persistent proteinuria due to impairment of the glomerular filter is blamed 
for damage and scarring of downstream tubules and interstitium [9]. In about 75% of 
primary MGN cases, the autoantibody target is the phospholipase A2 receptor (PLA2R) 
[9, 10]. Autoantibodies against a further podocyte membrane protein – thrombospondin 
type-1 domain-containing 7A – are present in the serum of 8-14% of PLA2R negative 
primary MGN patients [11]. It is likely that further autoantigens will be discovered as 
causes of primary MGN, which may turn out to be simply a collective term for 
autoimmune diseases targeting renal podocyte membranes.  
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Direct targets of the immune system located in the renal tubules and interstitium 
Anti-tubular basement membrane (TBM) disease, for example, is an autoantibody 
mediated form of progressive primary tubulointerstitial nephritis (TIN). Damage to the 
TBM occurs through both autoantibody deposition and activity of autoreactive T cells 
against the membrane’s 3M-1 glycoprotein [12]. Strong linear staining of the proximal 
TBM with IgG is visible with immunofluorescence microscopy. Light microscopy of 
these renal biopsies often shows interstitial inflammation with extensive fibrosis and 
small atrophic tubules [13]. 
 
TIN can also result from primary Sjögren’s syndrome (pSS), affecting about 10% of 
pSS patients. Although pSS is a systemic autoimmune condition characteristically 
affecting glandular epithelium, with renal involvement typically manifested by 
glomerulonephritis due to deposition of circulating immune complexes, development of 
TIN in pSS seems to result from a renal-directed immune process. Potential self-
antigens targeted by autoantibodies and autoreactive T cells in pSS include carbonic 
anhydrase and the hydrogen transporter H+-ATPase, which are found in both renal 
tubules and salivary glands [14]. pSS-associated TIN is characterised by lymphocyte 
infiltration of the tubular and interstitial compartments, accompanied by a large 
proportion of interstitial plasma cells. Though TIN in general is associated with 
subsequent tubular atrophy and interstitial fibrosis, often leading to CKD, pSS-
associated TIN usually takes a relatively benign course and often responds well to 
treatment with rituximab, a monoclonal antibody against the B cell marker CD20 [15]. 
 
Indirect immune-mediated renal disease 
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As for direct immune-mediated renal disease, the majority of indirect immune-mediated 
renal pathologies are due to autoimmunity, but some are the consequence of genetic 
defects in the complement system or haematologic malignancies such as multiple 
myeloma or Hodgkin lymphoma. Indirect kidney injury secondary to loss of immune 
homeostasis is caused by three major mechanisms: circulating immune complex 
deposition, dysregulation of the alternate complement pathway, and deposition of 
monoclonal immunoglobulins, though others are implicated, such as elevated systemic 
cytokines in podocytopathies and autoantibodies targeting the systemic vasculature 
causing thrombotic microangiopathy and downstream ischaemic damage, to which the 
renal tubular epithelium is especially vulnerable. 
 
Immune complex deposition in the glomerulus occurs in many systemic autoimmune 
diseases. In addition, immune complexes may also form in the context of infection – 
most frequently streptococcal and hepatitis B infection [1, 12]. Circulating immune 
complexes consist of several antibodies grouped around their target antigen, which in 
some cases is another antibody (e.g. rheumatoid factor). These complexes often settle 
in the glomerulus because of their size and become trapped, according to their charge, 
within various compartments of the glomerular filtration barrier. In some cases, 
complexes can form in situ, when a target antigen exogenous to the kidney becomes 
trapped within the glomerular basement membrane due to its relatively small size and 
positive charge [9]. Similarly, nucleosomes from apoptosed cells can become trapped 
in the negatively charged GBM [16], where they are subsequently bound by 
autoantibodies to the nucleosome component of eukaryotic cell chromosomes, which 
are present in the serum of some SLE patients and have been associated with an 
increased risk for developing lupus nephritis [17]. 
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Immune complexes damage the glomerular endothelium, epithelium and mesangium 
by activating circulating immune cells and kidney-intrinsic cells expressing Fc receptors. 
Activated cells secrete cytokines and vasoactive substances to create a pro-
inflammatory environment in the region local to immune complex deposition. In addition, 
the complement cascade is activated via the classical pathway, the endpoint of the 
cascade being the formation of the membrane attack complex, which injures 
surrounding cells, leading to further pro-inflammatory signalling [18]. Table 1 lists 
examples of GN caused by immune complex deposition associated with diseases 
involving loss of immune homeostasis. 
 
Over activity of the complement system leading to renal damage can be due to genetic 
mutations in complement regulatory components or autoimmune disease against 
components of the complement system. The alternative pathway of complement 
activation is based on the spontaneous breakdown of C3 into C3a and C3b which can 
bind to the cell surface. Other complement factors are added to form an enzymatic 
complex able to cleave further C3 and eventually C5, which is essential for the 
formation of the membrane attack complex. This system is regulated by several 
inhibitory factors. The cascade of the alternative pathway leading to the formation of C3 
convertase (C3bBb) is controlled by factors H and I. Mutations or autoantibodies 
against these can lead to increased activation of the C3 convertase, leading to 
significantly increased levels of activated C3 [20]. Additionally, the IgG autoantibody, 
C3 nephritic factor, stabilises C3 convertase preventing its inactivation. As a result, 
damaging C3 deposits can form in the glomerulus, activating downstream inflammatory 
cascades and promoting leukocyte infiltration. In dense deposit disease (DDD), small 
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band-like electron dense deposits of complement form along the GBM, leading to GBM 
thickening and dysfunction [21]. In addition to GBM deposits, C3 glomerulopathies also 
show varying degrees of mesangial C3 deposits, leading to mesangial cell proliferation 
and matrix expansion. In both DDD and C3 glomerulopathies, immunoglobulin deposits 
may co-localize with the complement deposits, though the immune complexes will be 
present in smaller proportions compared to those seen in true immune complex-
mediated renal diseases [1, 13, 18]. 
 
Injury of the renal vascular tree also can be mediated by conditions related to loss of 
immune homeostasis. Primary antiphospholipid syndrome (APS) is an autoimmune 
disease characterised by circulating antiphospholipid antibodies (aPLs), recurrent 
venous or arterial thrombosis and pregnancy-related problems. The aPLs, which 
include lupus anticoagulant (LA), anti-cardiolipin (aCL) and anti-β2-glycoprotein I (anti-
β2GPI), create a pro-coagulant state, which leads to thrombosis in the presence of a 
further pro-thrombotic factor, such as oxidative stress, surgical intervention, or infection. 
Anti-β2GPI, for example, binds β2GPI on the endothelial cell surface, inducing a pro-
coagulant and pro-inflammatory phenotype. aPLs also upregulate tissue factor 
expression, promote endothelial leukocyte adhesion, cytokine secretion, prostaglandin 
E2 synthesis and promote platelet aggregation and activation. They may further affect 
fibrinolysis and the natural anticoagulant annexin A5, thus increasing the pro-coagulant 
effect by decreasing natural anticoagulants [22]. Around 10% of patients with primary 
APS develop renal involvement [23]. Thrombosis can occur at any level of the renal 
vascular tree, from renal artery stenosis to renal vein thrombosis. The various 
intrarenal vascular lesions and their subsequent chronic effects on kidney tissue are 
grouped under the term APS nephropathy. Damage occurs from chronic narrowing of 
arteries by arteriosclerosis and acute or chronic occlusion of smaller arteries, arterioles 
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and capillaries by thrombotic microangiopathy, which can both lead to focal cortical 
atrophy or focal segmental glomerulosclerosis [24]. True immune complex-type 
deposits are not seen in the lesions, and injury to the renal parenchyma is mainly 
mediated by ischemia [22,23].   
 
Similar-appearing thrombotic microangiopathy lesions can be caused by haemolytic 
uraemic syndrome (HUS), either the classical diarrhoea-associated type or atypical 
non-diarrhoea associated HUS (aHUS). Classic HUS is caused by Shiga-toxin, which 
is produced by Shigella and certain enterohemorrhagic E. coli bacteria. The rarer 
aHUS is a consequence of dysregulation of the alternative complement pathway. Why 
deficiencies in the regulatory factors H and I sometimes cause C3 glomerulonephritis 
(C3GN) and other times aHUS is still unknown, though it is postulated that activation of 
C3 bound to endothelial surfaces mediates aHUS, while activation of C3 in the fluid 
phase leads to glomerular deposition and C3GN [1, 18]. Identification of the respective 
aberrant molecular pathways leading to the development of either C3GN or aHUS 
might advance treatment options for both conditions. 
 
Pauci-immune focal necrotising GN is a renal complication of systemic small vessel 
vasculitides often caused by autoantibodies to neutrophil cytoplasmic antigens (ANCA). 
ANCA-GN results in significant damage the glomerular vasculature and can 
demonstrate associated arterial damage, though by a different mechanism from APS 
and aHUS. ANCA-GN runs a rapidly progressive clinical course and displays a 
crescentic GN morphology on renal biopsy, with severe necrotising destruction of the 
glomerular tuft [25]. The pathological mechanisms of ANCA-GN are not clear. It may be 
initiated by glomerular injury, which activates neutrophils, leading to degranulation and 
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expulsion of neutrophil extracellular traps (NETs), as the first step of the tissue repair 
process. The expulsion of NETs in the glomerular capillaries releases the ANCA-
associated antigens (myeloperoxidase (MPO), proteinase 3 (PR3) and lysosome-
associated membrane glycoprotein 2), which are then bound by circulating ANCA 
autoantibodies [1]. Furthermore, in vivo studies have shown that PR3-ANCA can 
activate circulating neutrophils directly [25]. Autoreactive T cells have also been 
implicated as important factors in the pathogenesis of ANCA-GN [26]. Together, 
reactive oxygen species released by activated neutrophils, autoantibody binding to 
NETs and consequently broader activation of leukocytes, cause localised inflammation 
and complement activation within glomerular capillaries. This vascular inflammation 
leads to localised necrosis, resulting in destruction of the glomerular filter with clinically 
evident haematuria and rapidly diminishing renal function [1]. 
 
While the inciting immunopathologic events of indirect immune-mediated renal disease 
vary, there is considerable overlap in the final pathologic process of renal fibrosis 
leading to loss of renal function. As in direct immune-mediated renal disease, 
continuous renal insult eventually leads to CKD. 
 
Transplantation 
The immune-mediated effects on the kidney after transplantation are extraordinary. Not 
only is organ transplantation an artificial setting – one that the immune system was not 
designed to deal with in terms of tissue surveillance or peripheral tolerance [27] – the 
alloimmune response underlying transplant rejection is incredibly robust. 
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Recipient immune responses directed against the allograft can be viewed in our 
previous construct of direct immune-mediated renal injury resulting from loss of 
immune homeostasis. Allograft rejection can be mediated by alloreactive antibodies or 
T cells. Acute rejection typically occurs within days or weeks of transplantation, when a 
major immune reaction occurs. Chronic rejection on the other hand, is a slow process, 
during which low level immune activity causes continuous damage to the renal 
epithelium and vasculature leading to fibrosis and progressively declining kidney 
function [28]. 
 
Antibodies and T cells target the foreign major histocompatibility complex (MHC) and 
MHC-like molecules expressed on the graft endothelium and epithelium. Donor-
reactive T cells can be generated by pre-exposure to foreign MHC molecules, for 
example through a previous blood transfusion or pregnancy, by generation of 
pathogen-specific memory T cells cross-reactive to epitopes on donor cells, or by de 
novo activation of naïve T cells against graft antigens, achieved by interaction with DCs 
derived either from the donor graft or from the recipient. Donor-derived DCs directly 
activate recipient T cells via the foreign MHC that they express, regardless of the 
presented peptide antigen. Recipient DCs present, on self-MHC, peptides derived from 
donor-specific proteins and thus activate the T cells against donor cells indirectly [27]. 
In addition to the multiple adaptive immune pathways that can contribute to the 
development of the clinical rejection, the innate immune system probably also 
contributes to the initiation of transplant rejection [29]. Due to these complex 
mechanisms and the fact that the T cells respond so strongly to allogeneic MHC 
molecules, current immunosuppressive therapy to prevent transplant rejection is often 
not 100% effective [27, 28]. Furthermore, this therapy is complicated by the side effects 
of immunosuppression, and a difficult balance has to be struck between immune-
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mediated transplant loss and immunosuppression-related malignancies and 
opportunistic infections. 
 
Post-transplant immunosuppression is often achieved with calcineurin inhibitors, which 
are toxic to the kidneys themselves. Additionally, the immunosuppressed state can 
lead to another form of disease which would fall under our heading of indirect immune-
mediated renal disease, namely post-transplantation lymphoproliferative disorders 
(PTLD). PTLD includes several subtypes of lymphoma and is estimated to occur in up 
to 20% of transplant recipients [30]. The most common forms of PTLD are B cell 
lymphomas. They develop due to immortalisation of B cells, often in association with 
Epstein-Barr virus (EBV). Under normal conditions the abnormal cells are removed by 
cytotoxic T cells; however, in the immunocompromised patient this regulation cannot 
take place and lymphoma can develop. PTLD can occur after all types of transplant 
and in most tissues. Sometimes the tumour is located in the kidney, where its 
expansion separates the nephron elements, leading to decreased renal function. Local 
inflammation may occur but fibrosis and necrosis are uncommon [13, 30]. 
 
An important function of the immune system is the prevention of malignancy. Natural 
killer cells and cytotoxic T cells recognise and remove abnormal cells, but the level of 
surveillance is reduced during immunosuppression. The advances in 
immunosuppression and allograft survival have also improved the survival of transplant 
recipients. However, due to the length of immunosuppression, there is an increased 
risk of occurrence of tumours in general. Renal transplant recipients therefore appear 
to be at risk not only of PTLD but also of a variety of carcinomas [31]. More specific 
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immunosuppressive drugs are therefore required, so that a positive transplant outcome 
does not lead to serious malignancy. 
 
Immune involvement in the progression of renal disease 
The examples above illustrate how dysregulation of the immune system contributes to 
the initiation of renal disease. There is considerable overlap in the mechanisms by 
which both direct and indirect immune-mediated renal diseases are caused, and the 
progression of each eventually leads to chronic renal failure. The immune system plays 
a central role in this progression of renal diseases, including those initiated by non-
immunological mechanisms such as hypoperfusion or obstructive pyelonephritis. 
 
During acute kidney injury (AKI) following sterile tissue injury, for example after renal 
artery infarction or through toxins, intrarenal immune cells are activated. Damaged 
renal epithelial cells activate their stress response pathways, which lead to the 
secretion of cytokines and vasoactive factors [5]. In addition, resident macrophages 
and DCs are activated by danger-associated molecular patterns (DAMPs), which are 
released by activated renal epithelial and necrotic cells. Together the activated cells 
recruit further leukocytes and initiate an immune response to clear debris and necrotic 
tissue, before tissue repair can take place [5]. The immune response, though 
detrimental in the long term if sustained, is essential for the repair of tissue. Severe 
damage can rarely be restored, but the kidneys will often heal after moderate 
ischaemic injury. The mechanisms by which the immune system regulates the healing 
process are not fully understood. DCs, macrophages and regulatory T cells, as well as 
the cytokines IL-10 and IL-22, have been implicated [32, 33]. A phenotypic shift in the 
renal mononuclear phagocytes from the pro-inflammatory Ly6ChighMR- to the 
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Ly6ClowMR+ anti-inflammatory associated phenotype can be observed as part of normal 
resolution following the initial responses to AKI (Figure 2) [34]. It remains uncertain how 
this switch is triggered. 
 
In the absence of anti-inflammatory factors or after severe tissue damage, the immune 
system further contributes to the development and progression of CKD. As a 
consequence of any initial renal pathology, immune cells may infiltrate the damaged 
tissue in response to DAMPs and chemotactic factors. These cells appear to be 
activated in a way that does not promote healing and instead perpetuates the 
inflammatory process. Tissue damage also releases previously “hidden” antigens, 
which may be recognised by autoreactive T cells. This de novo formation of 
autoimmunity has been proposed as a mechanism sustaining the immune response 
[32]. Progressive remodelling eventually leads to tubular atrophy and interstitial 
scarring, which manifest clinically as worsening renal function [1]. 
 
Treatment for AKI and CKD is supportive, with the aim of slowing the progression to 
ESRD, which requires renal replacement therapy. Targeted treatments have not been 
developed yet, and are also not available for many of the immune-mediated renal 
diseases. The latter are commonly treated by general immunosuppression, for example 
with corticosteroids. However, several of the target antigens of primary renal 
autoimmune diseases have been identified, meaning directed treatment could 
theoretically be possible. For example, a murine model of anti-GBM-disease was used 
to demonstrate that disease activity could be reduced by induction of mucosal 
tolerance through nasal administration of an immunodominant peptide from the anti-
GBM target α3(IV)NC1 [35]. However, for many diseases the exact target antigen and 
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its major epitopes are still unknown. In addition, clinical manifestation of the disease 
often occurs relatively late in the pathogenesis, when substantial damage has already 
occurred. Although knowledge of genetic susceptibility has increased, environmental 
factors are still essential to the initiation of autoimmune diseases, so that prophylactic 
treatment is not possible or feasible at this stage. 
 
It would be interesting to determine whether or not the progression to ESRD can be 
stopped by a single intervention, regardless of the initial aetiology of renal disease. 
Perhaps the immune system itself can be harnessed to promote healing. Several 
studies in experimental ischaemic AKI suggest that cellular therapy with DCs and 
regulatory T cells could promote tissue repair [36, 37, 38]. These treatments appear 
effective during the initial injury, but early administration in normal clinical conditions is 
usually not possible [32]. Further research is therefore needed to find treatment options, 
which could be used in clinical practice. First steps could include further investigation of 
the immune responses and tissue repair in patients with AKI which does not progress 
to CKD. The differentiation of T cell populations might be of particular interest. 
Moreover, anti-GBM disease can sometimes be self-limiting and regulatory cell 
populations have been described in the later phases [39]. Additional research into 
these T cells might further aid in the understanding of the decision point between 
regulatory or effector T cell activation. 
 
To conclude, the immune system plays a central role in the initiation, progression and 
resolution of renal disease (summarised in Figure 3). Our understanding of renal 
resident immune cells and of the varied immune mechanisms underlying renal disease 
is increasing and may aid in the design of future targeted immune-based therapies to 
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restore homeostasis of the immune system, rather than simply suppress it, in order to 
promote appropriate healing and prevent progression to CKD and ESRD. 
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Tables and Figure Legends 
 
 
 
 
Figure 1: Molecular Pathogenesis of Anti-Glomerular Basement Membrane Disease 
An unknown stimulus directs production of anti-GBM autoantibodies. The principal target for the 
anti-GBM antibodies (which are typically IgG 1 and 3 but sometimes IgA or IgM) is the NC1 
domain of the alpha-3 chain of type IV collagen (α3(IV) chain), one of six genetically distinct 
gene products found in basement membrane collagen. The antigen-antibody binding activates 
the complement cascade and further inflammatory cell recruitment leads to chronic inflammation 
and fibrosis. 
 
Location of 
glomerular 
immune-complex 
deposits 
Associated 
Glomerulonephritides, with 
examples 
Associated Diseases involving 
loss of immune homeostasis, 
examples 
Subendothelial Membranoproliferative GN 
IgA nephropathy 
Lupus nephritis (classes III & IV)* 
Autoimmune disease (e.g. 
Sjögren’s syndrome, scleroderma, 
SLE) 
Mesangial Membranoproliferative GN 
IgA nephropathy 
Lupus nephritis (classes I & II)* 
Autoimmune disease (e.g. Coeliac 
disease, SLE) 
Inflammatory disease (Crohn’s 
disease) 
Subepithelial Membranoproliferative GN 
Infection-related GN 
Membranous GN 
Lupus nephritis (class V) 
Autoimmune disease (e.g. SLE, 
anti-PLA2R disease) 
 
 
 
Table 1: Immune complex mediated glomerulonephritis 
 
In addition to the listed conditions, other autoimmune diseases may uncommonly lead to 
immune complex deposition. Abbreviations: GN, glomerulonephritis; SLE, systemic lupus 
erythematosus; C’, complement.  * International Society of Nephrology/Renal Pathology 
Society 2004 Classification of Lupus Glomerulonephritis [19] 
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Figure 2: Progression versus Resolution of Inflammatory Processes in the Kidney 
Pathways following acute kidney injury and activation of the renal sentinel immune cells. Initial 
switch to inflammatory Ly6highMR- mononuclear phagocyte phenotype and inflammatory cell 
recruitment. Phenotypic switch to anti-inflammatory Ly6ClowMR- favours tissue repair and 
return to immune homeostasis. However, repeat or prolonged inflammation leads to necrosis of 
cells, fibrotic change and chronic kidney disease. 
 
Figure 3: The central role of the immune system in renal pathology 
CKD, chronic kidney disease; ESRD, end stage renal disease 
 



